Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT00153803 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

245

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Non-small Cell Lung Cancer
NSCLC

Interventions

DRUG: Erlotinib (tarceva)
DRUG: Placebo

Sponsor

Dartmouth-Hitchcock Medical Center

Collaborators

[object Object]
[object Object]